A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.

Item
http://www.wikidata.org/entity/Q37124978
Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia APrimary percutaneous coronary intervention for acute myocardial infarction in a young female with idiopathic thrombocytopenic purpura: a case report and review.Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals.Platelets as delivery systems for disease treatmentsSuccessful Ultrasound-Guided Femoral Nerve Blockade and Catheterization in a Patient with Von Willebrand DiseaseUtility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice.Recombinant factor VIII in the management of hemophilia A: current use and future promise.Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.Development and introduction of recombinant factor VIII--a clinician's experience.A review of immune tolerance induction with Haemate P in haemophilia A.Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.Acquired hemophilia as the cause of life-threatening hemorrhage in a 94-year-old man: a case report.Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model.
P2860

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.

Item
http://www.wikidata.org/entity/Q37124978
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A systematic overview of the f ...... tory and clinical performance.
@en
A systematic overview of the f ...... tory and clinical performance.
@nl
type
label
A systematic overview of the f ...... tory and clinical performance.
@en
A systematic overview of the f ...... tory and clinical performance.
@nl
prefLabel
A systematic overview of the f ...... tory and clinical performance.
@en
A systematic overview of the f ...... tory and clinical performance.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P50
P577
P5875
P698
P356
P1433
P1476
A systematic overview of the f ...... tory and clinical performance.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1600-0609.2008.01049.X
P433
P50
P577
P5875
P698